OM1's Foundation Model Predicts More Than 1,700 Clinical Outcomes

For a regulator reviewing a new drug or a doctor considering a treatment plan, the most important question is often the simplest: what happens to the patient? The answer, however, has historically been locked away in fragmented electronic health records, unstructured clinical notes, and disconnected lab results. OM1, a Boston-based healthtech company founded in 2015, is betting that a foundation model trained on a staggering volume of longitudinal patient data can finally unlock those answers at scale [Perplexity Sonar Pro Brief].

Its core asset, the PhenOM AI model, was trained and validated on what the company reports are longitudinal medical histories from more than 400 million de-identified patient records [Business Wire, November 2026]. The model's published validation claims it can produce predictions across more than 1,700 distinct clinical outcomes, with 80% of its predictive tasks reaching an area under the receiver operating characteristic (AUROC) score of at least 0.70 [Business Wire, November 2026] [biztoc.com, Retrieved 2026]. For context, an AUROC of 0.70 suggests a model with fair to good discriminatory ability, a meaningful benchmark for initial validation in a field where many predictive tools struggle to move beyond academic papers.

The Physician-Founder's Data Playbook

The company's trajectory is deeply tied to its founder and CEO, Dr. Richard Gliklich. A professor of otolaryngology at Harvard Medical School, Gliklich is not a newcomer to the business of patient outcomes [Patientless Podcast, Mendel AI]. He previously founded Outcome Sciences, a real-world research company he led until its acquisition by clinical research giant Quintiles in 2011 [Business Wire, October 2011]. He also serves as a senior editor for a key U.S. Agency for Healthcare Research and Quality handbook on patient registries, giving him a front-row seat to the regulatory frameworks his company's data must satisfy [PMWC Precision Medicine World Conference, 2026]. This background suggests OM1 was built not just by technologists, but by someone who understands the exacting standards of evidence required by the FDA and payers.

Gliklich's prior exit and credibility have attracted a formidable roster of investors over four major funding rounds, amassing approximately $176 million in total disclosed financing [Perplexity Sonar Pro Brief]. The table below outlines the company's funding journey, which shifted from traditional venture capital to include strategic healthcare players.

Date	Round	Amount	Lead Investor(s)
April 2017	Series A	$15 million	General Catalyst [Healthcare Innovation, April 2017]
May 2018	Series B	$21 million	Polaris Partners [MobiHealthNews, May 2018]
December 2019	Series C	$50 million	Scale Venture Partners [TechCrunch, December 2019]
July 2021	Series D+	$85 million	D1 Capital Partners, Kaiser Permanente, Breyer Capital [MedCity News, July 2021]

The 2021 round is particularly notable for the participation of Kaiser Permanente as a co-lead, signaling a strategic partnership with one of the nation's largest integrated health systems [Global Corporate Venturing, July 2021]. This kind of validation from a provider that both delivers care and bears financial risk for outcomes is a significant signal in the healthcare data space.

From Data Cloud to Clinical Insight

OM1's product suite is built atop its Real-World Data Cloud, which aggregates, standardizes, and enriches clinical information from electronic health records, laboratories, claims, and patient-reported sources [Perplexity Sonar Pro Brief]. The company then packages this data and its analytical capabilities into several product lines, including OM1 Orion, Lyra, and Polaris, which support use cases from real-world evidence generation for drug approvals to patient identification and clinical decision support [OM1, May 2024].

The company has focused its disease coverage on complex, chronic conditions where longitudinal tracking is critical, including dermatology, rheumatology, cardiology, and neurosciences [Perplexity Sonar Pro Brief]. This focus is evident in its partnerships. In one project with the American Academy of Dermatology, OM1's Patient Finder tool is being combined with the Academy's DataDerm registry, which contains over 63 million de-identified encounters, to support research initiatives [YesPress, Retrieved 2026]. Another partnership with analytics firm Panalgo integrates OM1's PremiOM datasets directly into a platform used by life sciences researchers [Owler Company Profile, Retrieved 2026].

The Risks of a Regulated Frontier

For all its promise, OM1's ambitious bet faces several inherent challenges in the highly regulated healthcare market. The company's success hinges on a few critical, interdependent factors.

• Clinical validation. While the company has published high-level validation metrics for its PhenOM model, the true test will be the adoption of its predictions in peer-reviewed studies and, ultimately, in clinical guidelines. An AUROC of 0.70 is a start, but regulators and clinicians will demand proof of consistent performance across diverse patient populations and real-world settings.
• Data liquidity and quality. OM1's networks automate collection from various systems, but the 'garbage in, garbage out' principle remains a perpetual risk in healthcare data [MedCity News, July 2021]. The value of its 400-million-record dataset depends entirely on the consistency, completeness, and clinical relevance of the data flowing in from its partner networks.
• Competitive landscape. OM1's differentiation rests on its AI-driven predictive layer and disease-specific longitudinal data, but it must continually prove this offers a tangible advantage over more conventional analytics services.

The company's most plausible answer to these risks is its founder's deep regulatory experience and its strategic capital. Gliklich's history with the AHRQ and his prior company's acquisition by Quintiles suggest a focus on building tools that meet the stringent requirements of the industry's most demanding customers from day one.

Measuring What Matters for Patients

The ultimate test for OM1's technology will be its impact on patient care in chronic diseases. Consider a patient with peripheral artery disease (PAD), a condition that impairs blood flow to the limbs and can lead to severe complications. Today, a physician's decision on treatment,whether it's medication, a stent, or surgery,is based on a mix of clinical guidelines, imaging studies, and instinct. The long-term outcome for that specific patient, however, remains a probabilistic guess.

OM1's platform aims to replace that guess with a data-driven prediction. The company has cited work where its OM1 Orion product was used to identify which PAD patients were more or less likely to experience negative outcomes following certain treatments [OM1, Retrieved 2026]. This is the practical endpoint of its massive data effort: moving the standard of care from reactive to predictive, one clinical decision at a time. For the millions of patients living with rheumatological, dermatological, or neurological conditions, that shift could mean fewer ineffective treatments, fewer adverse events, and a clearer path to managing their health.

Sources

1. [Perplexity Sonar Pro Brief] OM1 Company Brief | https://startupintros.com/orgs/om1
2. [Business Wire, November 2026] OM1 Publishes Validation Results from a Single Healthcare Foundation Model Across More than 1700 Predicted Clinical Outcomes | https://www.businesswire.com/news/home/20261102423771/en/OM1-Publishes-Validation-Results-from-a-Single-Healthcare-Foundation-Model-Across-More-than-1700-Predicted-Clinical-Outcomes
3. [biztoc.com, Retrieved 2026] Validation metrics for PhenOM | https://biztoc.com
4. [Patientless Podcast, Mendel AI] Richard Gliklich, CEO of OM1 on Patientless Podcast #003 | https://www.mendel.ai/post/podcast003
5. [Business Wire, October 2011] Quintiles Acquires Outcome Sciences | https://www.businesswire.com/news/home/20111003005327/en/Quintiles-Acquires-Outcome-Sciences
6. [PMWC Precision Medicine World Conference, 2026] Rich Gliklich - 2026sv - PMWC Precision Medicine World Conference | https://pmwcintl.com/speaker/rich-gliklich-256_om1_2026sv/
7. [Healthcare Innovation, April 2017] Healthcare Analytics Startup OM1 Raises $15M | https://www.hcinnovationgroup.com/analytics-ai/news/13028407/healthcare-analytics-startup-om1-raises-15m
8. [MobiHealthNews, May 2018] Health outcomes AI company OM1 lands $21M in Series B funding | https://www.mobihealthnews.com/news/health-outcomes-ai-company-om1-lands-21m-series-b-funding
9. [TechCrunch, December 2019] Applying big data analytics to patient records, OM1 offers insights to hospitals and pharma | https://techcrunch.com/2019/12/17/applying-big-data-analytics-to-patient-records-om1-offers-insights-to-hospitals-and-pharma/
10. [MedCity News, July 2021] OM1 gains $85M to expand clinical data networks, AI models | https://medcitynews.com/2021/07/om1-gains-85m-to-expand-clinical-data-networks-ai-models/
11. [Global Corporate Venturing, July 2021] OM1 turns to Kaiser Permanente in $85m round | https://globalventuring.com/corporate/om1-turns-to-kaiser-permanente/
12. [OM1, May 2024] OM1 Product Suite | https://www.om1.com/
13. [YesPress, Retrieved 2026] American Academy of Dermatology project with OM1 | https://www.yespress.com
14. [Owler Company Profile, Retrieved 2026] Panalgo and OM1 partnership | https://www.owler.com
15. [OM1, Retrieved 2026] OM1 Orion use case for PAD | https://www.om1.com